Hot Investor Mandate: Global Pharmaceutical Company with Japan Headquarters Seeks Collaboration & In-Licensing Opportunities in CNS, Autoimmune Disease, Rare/Orphan Indications

1 Nov

A global pharmaceutical company headquartered in Japan with strong USA operations is actively seeking global collaboration and in-licensing opportunities within the early-stage ecosystem to strengthen their pipeline.

The company is seeking innovative therapies with highest focus on the following: CNS diseases, autoimmune diseases, and rare/orphan diseases. The company’s pipeline covers other indications as well and the company may review such opportunities on a case-by-case basis. The company is open to all stages of development, and those who have passed PoC are considered most ideal. The company has a strong interest in excellent technologies in biologics, including therapeutic antibodies, vaccines, and nucleic acid drugs, as well as cell-based phenotypic screening models of CNS or skeletal muscle diseases for new drug discovery.

The company seeks to work with management teams with strong scientific expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: